Skip to main content
Probi logo

Probi — Investor Relations & Filings

Ticker · PROB ISIN · SE0001280355 LEI · 5493004CJOCT273MU397 ST Manufacturing
Open in API
Filings indexed 410 across all filing types
Latest filing 2012-12-11 M&A Activity
Country SE Sweden
Listing ST PROB

About Probi

https://www.probi.com/

Probi is a global biotics company specializing in the research, development, and manufacturing of clinically documented probiotic strains. The company provides biotic solutions for dietary supplements and functional foods, targeting specific health needs across various life stages. Its portfolio addresses key areas such as digestive, immune, mental, and metabolic health, alongside specialized formulations for women, children, and healthy aging. Probi's offerings are founded on extensive scientific research and clinical studies to ensure proven efficacy in supporting human health.

Recent filings

Filing Released Lang Actions
Probi and Viva 5 Corporation form Probiotic Business Development Alliance in North America
M&A Activity Classification · 1% confidence The document is a press release announcing a business development alliance and licensing agreement between Probi and Viva 5 Corporation regarding probiotic ingredients in North America. This announcement details a strategic partnership, market analysis, and future commercial plans. It is not a formal regulatory filing like a 10-K, an earnings release (ER), a dividend notice (DIV), or a management discussion (MDA). Since it announces a significant business development/partnership, it falls under the category of general corporate news or a strategic update that doesn't fit the highly specific categories like M&A (TAR) or Capital Change (CAP). Given the options, the most appropriate general category for significant corporate announcements that aren't standard financial reports or insider trades is Regulatory Filings (RNS), which serves as a broad category for miscellaneous regulatory disclosures, especially when the core content is a strategic business announcement.
2012-12-11 English
Probi stärker affärsutvecklingen i USA
Regulatory Filings Classification · 1% confidence The document is titled "PRESSMEDDELANDE" (Press Release) and announces a new business development agreement between Probi and Viva 5 regarding marketing rights for Probi's products in North America. It includes quotes from management and concludes with a statement that the information is subject to disclosure requirements under securities laws. This type of announcement, detailing a significant business event (a partnership/agreement) that is not a standard periodic financial report (like 10-K or IR) or a specific insider transaction (DIRS) or dividend (DIV), typically falls under general regulatory announcements or news releases. Since it is a specific business development announcement and not a standard financial filing, and it doesn't fit other specific categories like M&A (TAR) or Capital Change (CAP), the most appropriate classification is Regulatory Filings (RNS) as a general regulatory announcement, or potentially a general news release if RNS is interpreted broadly. Given the context of financial reporting databases, RNS serves as the catch-all for material, non-standard announcements. It is not an Earnings Release (ER) as it doesn't contain financial results, nor is it a Call Transcript (CT) or Investor Presentation (IP).
2012-12-11 Swedish
Resultat från Probis Kliniska Studier inom Immun- och Maghälsa
Regulatory Filings Classification · 1% confidence The document is a short press release (1623 characters) announcing the completion and preliminary negative results of clinical studies in immunology and gut health. It explicitly states that the company does not intend to file for health claims with EFSA based on these results. It is an announcement regarding research outcomes and future regulatory strategy, not a full financial report (like 10-K or IR), a dividend notice, or a management change. Since it is a specific announcement about research/regulatory strategy that doesn't fit perfectly into the defined categories like ER, AR, or LTR, and it is a regulatory-style press release, the most appropriate general category is Regulatory Filings (RNS), as it serves as a general regulatory disclosure. Alternatively, given the content relates to clinical studies and potential future regulatory submissions (EFSA), it could be argued as LTR (Legal Proceedings Report) if the negative results were considered a material event impacting future regulatory standing, but RNS is a safer fallback for general, non-financial, non-management press releases.
2012-11-29 Swedish
Results from Probi’s Clinical Studies in Immune and Gut Health
Earnings Release Classification · 1% confidence The document is a short press release dated November 29, 2012, announcing the results of two clinical studies which 'did not meet expectations' and stating that the company will not apply for health claims with EFSA at this point. It contains key business updates, quotes from the CEO, and contact information. It is not a full financial report (10-K, IR), a transcript (CT), or a formal dividend/share change notice. Since it is an announcement of business/research developments that doesn't fit the specific categories like ER (Earnings Release) or LTR (Legal Proceedings), and it is a general regulatory disclosure ('Information submitted for publication'), it best fits the general 'Regulatory Filings' fallback category (RNS), as it is a mandatory disclosure under Swedish law that doesn't align with the more specific options. FY 2012
2012-11-29 English
Valberedning i Probi AB
Board/Management Information Classification · 1% confidence The document is a press release written in Swedish ("PRESSMEDDELANDE") announcing the composition of the Nomination Committee ("Valberedning") for the upcoming Annual General Meeting ("årsstämman 2013"). It also mentions the date and location of the AGM. This content directly relates to the preparation and governance surrounding the Annual General Meeting, specifically concerning the nomination of board members. This aligns best with the 'AGM Information' category (AGM-R), which covers presentations and materials shared during the AGM, and by extension, preparatory materials like nomination committee announcements.
2012-10-24 Swedish
Nomination Committee at Probi AB
AGM Information Classification · 1% confidence The document is a press release announcing the composition of the Nomination Committee for the upcoming 2013 Annual General Meeting (AGM) and providing details (date, time, location) for that AGM. It also outlines procedures for shareholders to submit proposals for the AGM agenda. Since the core subject matter revolves around the preparation and logistics for the Annual General Meeting, the most appropriate classification is AGM Information (AGM-R), which covers presentations and materials shared during the AGM, and by extension, preparatory announcements related to it. It is not a DEF 14A (Remuneration) or DVA (Voting Results), but rather an announcement concerning the meeting itself.
2012-10-24 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.